Colorectal cancer (CRC) is the third most common cancer worldwide and is associated with a poor clinical outcome and survival. Therefore, the development of novel therapeutic agents for CRC is imperative. Atractylenolide I (AT-I) is a sesquiterpenoid lactone derivative of Rhizoma Atractylodis macrocephalae that exhibits diverse biological activities, including anti-cancer activities. However, the effects and potential mechanism of AT-I in CRC have yet to be fully elucidated. In this study, we aimed to examine the anti-cancer properties of AT-I and the associated functional mechanisms in vitro and in vivo. We found that AT-I treatment significantly suppressed the viability of CRC cell lines and inhibited colony formation, but to a lesser extent in NCM460 cells. Annexin V/PI staining showed that AT-I induced apoptosis in CRC cells, accompanied by increased caspase-3 and PARP-1 cleavage, enhanced expression of Bax, and reduced expression of Bcl-2. Furthermore, AT-I blocked cell glycolysis by inhibiting both glucose uptake and lactate production in CRC cells, and specifically downregulated the expression of the rate-limiting glycolytic enzyme HK2. In contrast, it had no discernable effects on the glycolytic enzymes PFK and PKM2. A mechanistic study revealed that AT-1 negatively regulates STAT3 phosphorylation through direct interaction with JAK2, thereby inhibiting its activation. Moreover, restoring the expression of STAT3 reversed the effect of AT-I on apoptosis and glycolysis in CRC cells. In vivo results revealed that AT-I significantly suppressed tumor growth in HCT116-xenografted mice. Collectively, our findings indicate that the anti-cancer activity of AT-I in CRC is associated with the induction of apoptosis and suppression of glycolysis in CRC cells, via the disruption of JAK2/STAT3 signaling. Our preliminary experimental data indicate that AT-I may have applications as a promising candidate for the treatment of CRC.

Keywords: atractylenolide I, colorectal cancer, apoptosis, glycolysis, JAK2, STAT3
INTRODUCTION

Colorectal cancer (CRC) is the third most commonly diagnosed cancer and the second leading cause of cancer-related deaths worldwide (Arnold et al., 2017; Bray et al., 2018). Recent statistics have indicated that 1.8 million CRC cases are diagnosed annually and that each year there are 881,000 CRC-related deaths worldwide (Bray et al., 2018). Despite the effectiveness of surgery, radiotherapy and chemotherapy, these strategies remain undesirable due to high rates of recurrence, drug resistance and potent side effects (Eng, 2009). Therefore, there is a pressing need to develop more effective preventive strategies and therapeutic drugs for CRC. Furthermore, a better understanding of the mechanisms underlying the anti-cancer effects of drugs is critical.

Atractylenolide I (AT-I, chemical structure is shown in Figure 1A), is a eudesmane-type sesquiterpenoid lactone derivative of Rhizoma Atractyloidis macrocephalae, which is a plant commonly used in traditional Chinese medicine (Zhu et al., 2018). Pharmacokinetic studies in rats have demonstrated that, after oral administration, AT-I is readily absorbed and persists for extended periods of time, suggesting good oral bioavailability (Wang et al., 2008). AT-I has a wide range of biological and pharmacological properties, including neuroprotective, anti-allergic, anti-inflammatory, and anti-cancer activities (Wang et al., 2009; Lim et al., 2012; More and Choi, 2017; Xiao et al., 2018). Previous studies have shown that AT-I is beneficial in treating various cancers through the regulation of different molecules and pathways. For example, AT-I has been shown to induce the G2/M phase of the cell cycle and cellular apoptosis in ovarian cancer cells by inhibiting the phosphatidylinositol 3-kinase/Akt/mammalian target of the rapamycin (PI3K/Akt/mTOR) pathway (Long et al., 2017). In addition, AT-I induces apoptosis in lung cancer cells, both in vitro and in vivo, via the mitochondrial-mediated apoptotic pathway (Liu et al., 2013). These findings indicate that AT-I has potential as a drug compound for cancer treatment. A previous clinical study has shown that oral administration of AT-I to gastric cancer cachexia for six weeks restores patient appetite performance status without any toxic effects (Liu et al., 2008). These studies indicate that AT-I is a safe and promising candidate for cancer treatment. Moreover, AT-I has been shown to reduce intestinal adenoma formation through elevating autophagic flux via a decrease in D-dopachrome tautomerase (Li et al., 2018). However, the effects of AT-I in CRC have yet to be clarified, and further investigations are required in order to determine the underlying mechanisms.

One of the hallmarks of all cancer cells is dysregulated energy metabolism (Cairns et al., 2011; Hanahan and Weinberg, 2011). Cancer cells preferentially utilize glucose via the glycolytic pathway rather than through the typical oxidative phosphorylation, which is known as the Warburg effect. This effect increases both glucose uptake and utilization to meet the high energy demands of cancer cells and also maintains cancer cell redox homeostasis, thereby contributing to the promotion of cancer cell growth (Bensinger and Christofk, 2012; Liberti and Locasale, 2016). Therefore, the disruption of this glycolytic pathway has become a major area of focus in the development of novel anti-cancer drugs, as exemplified by those strategies aimed at inhibiting key rate-limiting glycolytic regulatory enzymes, including hexokinase 2 (HK2), phosphofructokinase (PFK), or pyruvate kinase M2 (PKM2) (Scatena et al., 2008; Ganapathy-Kanniappan and Geschwind, 2013). Therefore, the inhibition of HK2, PFK, or PK to attenuate or suppress glycolysis in cancer cells is currently considered a potentially effective anti-cancer strategy (Pelicano et al., 2006). Identification of small-molecule inhibitors of these enzymes is a key priority in the development of compounds that could potentially promote a reduction in cancer cell proliferation, as well as an increase in cancer cell death.

In this study, we discovered that AT-I potentially inhibits CRC cell proliferation and induces CRC cell apoptosis. We also found that AT-I reduces HK2 expression and glycolysis in CRC cells, and that the mammalian target of the JAK2/STAT3 signaling pathway is crucial for the AT-I-mediated decrease in HK2 expression, glycolytic regulation, and cell apoptosis. Collectively, our results point to a novel mechanism whereby AT-I can exert therapeutic efficacy against cancer, potentially offering new opportunities for drug development.

MATERIALS AND METHODS

Reagents and Antibodies
AT-I and AG490 were purchased from Selleck (Houston, TX, USA). Stock solutions of AT-I (100 mM) and AG490 (10 mM) were dissolved in dimethyl sulfoxide (DMSO). Antibodies against HK2, PKM2, PFK, JAK2, phospho-JAK2, STAT3, and phospho-STAT3 were purchased from Cell Signaling Technology (Beverly, MA, USA). Antibodies against caspase-3, PARP, cleaved caspase-3, cleaved PARP, Bcl-2, Bax, and β-actin were purchased from Abcam (Cambridge, UK).

Cell Lines and Culture
The human CRC cell lines HCT116 and SW480 were purchased from the Shanghai Institute for Biological Sciences (Shanghai, China). Human normal colon mucosal epithelial cell line NCM460 was obtained from INCELL (San Antonio, TX, USA). These cells were cultured in Mycos’ 5A (HCT116), L15 (SW480) and DMEM (NCM460) media (Invitrogen, Carlsbad, CA, USA), respectively, supplemented with 10% FBS (Invitrogen, Carlsbad, CA, USA), 100 U/mL penicillin, and 100 μg/mL streptomycin in a humidified atmosphere of 95% air and 5% CO2 at 37°C.

Cell Viability Assay
Cell viability was evaluated using a Cell Counting Kit-8 (CCK-8) assay kit (Dojindo Laboratories Tokyo, Japan). Briefly, the cells were seeded into 96-well tissue culture plates at a density of 1 × 10^4 cells/well and treated with the indicated concentrations of AT-I. After 24 or 48 h of incubation, 10 μL of CCK-8 solution was added and then the cells were incubated for a further 1 h. The absorbance of cells at 450 nm was measured using a microplate reader (Bio-Rad Laboratories, Richmond, CA, USA).
Incorporation Assay
CRC cells were seeded in 96-well plates (5000 cells per well). After incubation for 24 h, the cells were pretreated with DMSO or AT-I for 24 h. Thereafter, 50 μM EdU (Ribobio, Guangzhou, China) was added to each well and following incubation at 37°C for 2 h, the cells were fixed with 4% formaldehyde for 30 min and then incubated with 2 mg/mL glycine for 5 min. After five washes with PBS, the cells were incubated with 100 μL of a 1× Apollo reaction cocktail for 30 min, following which, 1× Hoechst 33342 (5 μg/mL) was used to stain the nuclei for 30 min at room temperature. Cells were visualized in three fields of view/well.

5′-Ethynyl-2′-Deoxyuridine (EdU) Incorporation Assay
CRC cells were seeded in 96-well plates (5000 cells per well). After incubation for 24 h, the cells were pretreated with DMSO or AT-I for 24 h. Thereafter, 50 μM EdU (Ribobio, Guangzhou, China) was added to each well and following incubation at 37°C for 2 h, the cells were fixed with 4% formaldehyde for 30 min and then incubated with 2 mg/mL glycine for 5 min. After five washes with PBS, the cells were incubated with 100 μL of a 1× Apollo reaction cocktail for 30 min, following which, 1× Hoechst 33342 (5 μg/mL) was used to stain the nuclei for 30 min at room temperature. Cells were visualized in three fields of view/well.

**Figure 1** | AT-I inhibits human CRC cell proliferation. (A) Chemical structure of AT-I. (B) Viability of NCM460, HCT116 and SW480 cells measured using the CCK-8 assay after treatment with different concentrations of AT-I for 24 or 48 h. (C) CRC cells were incubated with 0, 100, or 200 μM AT-I for 24 h, followed by further analysis using the EdU incorporation assay. Representative images are displayed. Scale bar = 100 μm. The EdU incorporation rate (the ratio of EdU-positive CRC cells to total Hoechst 33342-positive CRC cells) is shown. (D) Colony formation of CRC cells was determined following treatment with the indicated concentrations of AT-I. Left: representative images of the colonies. Right: statistical analysis showing the percentage of colonies relative to the control cells. **p < 0.01 and ***p < 0.001 versus the control group without any treatment.
under a fluorescence microscope (Carl Zeiss). The EdU incorporation rate was expressed as the ratio of EdU-positive cells to total Hoechst 33342-positive cells.

**Colony Formation Assay**

CRC cells were treated with AT-I at the indicated concentrations and then transferred to a six-well cell culture plate at a density of $5 \times 10^3$ cells/well. After further incubation for 14 days, the cells were fixed with 4% paraformaldehyde for 15 min and then stained with 0.1% (wt/vol) crystal violet. After incubation for 10 min, the cells were washed with PBS and then photographed using a digital camera. Colonies containing more than 50 cells were counted.

**4, 6-Diamido-2-Phenylindole Hydrochloride (DAPI) Staining**

Cells were stained with DAPI (Sigma-Aldrich, St Louis, MO, USA) to evaluate nuclear changes associated with apoptosis. Briefly, the CRC cells were seeded at a density of $1 \times 10^5$ cells/well in six-well tissue culture plates, and then treated with the indicated concentrations of AT-I for 24 h. Thereafter, the cells were washed with PBS, followed by fixation with 4% paraformaldehyde for 30 min. After washing with PBS, the cells were stained with DAPI for 5 min. Samples were then mounted on a glass slide and the nuclear morphologies were observed using a BX51 fluorescence microscope (Olympus, Tokyo, Japan).

**Annexin V/Propidium Iodide (PI) Double Staining Assay**

Apoptosis-mediated cell death was determined using an FITC Annexin V Apoptosis Detection Kit (BD Biosciences, San Jose, CA, USA) following the manufacturer’s guidelines. Briefly, CRC cells (1 $\times 10^5$ cells per well) were seeded in six-well tissue culture plates. After exposure to AT-I at the indicated concentrations for 24 h, both the attached and floating cells were collected. The cells were washed with PBS, then resuspended in 100 $\mu$L of binding buffer and stained with Annexin V-FITC and PI at room temperature for 15 min in the dark. Subsequently, 400 $\mu$L of binding buffer was added to each sample and the samples were examined using a FACSscan flow cytometer (Becton Dickinson, Franklin Lakes, NJ, USA). Analysis of the data was performed using FlowJo software.

**Measurement of Glucose Uptake and Lactate Production**

CRC cells (1 $\times 10^5$ cells/well) were seeded into six-well plates and treated with the indicated concentrations of AT-I for 24 h. The supernatant was collected and centrifuged to remove the cell debris. The glucose and lactate levels in the supernatant were measured using a glucose assay kit and a lactate assay colorimetric kit (Abcam, Cambridge, UK), respectively, according to the manufacturer’s instructions. Glucose consumption and lactate production were calculated based on a standard curve and normalized by cell numbers.

**STAT3 Overexpression Plasmid and Transfection**

The human STAT3 expression plasmid pCMV3-STAT3-FLAG and empty vector pCMV3-C-FLAG were purchased from Sino Biological Inc. (Beijing, China). The CRC cells were transfected with the STAT3 overexpression vector or empty vector using Lipofectamine 2000 (Invitrogen, Grand Island, NY, USA) following the manufacturer’s instructions. After a 48 h transfection, the cells were treated with AT-I for 24 h and then harvested for analysis.

**Western Blot Analysis**

Total cell lysates were obtained by lysing with RIPA buffer (Beyotime, Nanjing, China) containing protease inhibitors. The protein concentration was determined using the Bradford assay (Bio-Rad Laboratory, Inc., Hercules, CA, USA). Proteins from each sample were separated by electrophoresis and then transferred to a PVDF membrane. Following blocking for 1 h at room temperature, the membrane was incubated with a 1:1000 dilution of primary antibodies overnight at 4°C. The following day, the membrane was washed and incubated with HRP-conjugated secondary antibodies (1:5000; Abcam, Cambridge, UK). Protein bands were developed using ECL Prime Western Blotting Detection reagent (GE Healthcare, Buckinghamshire, UK), and images were obtained using an ECL chemiluminescence instrument (Tanon Science and Technology Co., Ltd., Shanghai, China). Quantification of protein band density was performed using Image J software. Signals were densitometrically quantified and normalized to β-actin expression.

**Molecular Docking**

Autodock vina 1.1.2 was utilized for molecular docking to further study the interaction mode between AT-I and JAK2. The crystal structure of the JAK2 (PDB ID: 4BBE) was obtained from RCSB Protein Data Bank. The 3D structure of AT-I was constructed by ChemBio3D Ultra 14.0 software. The docking study was performed using the AutoDock Tools to generate the docking input files. Prior to docking, non-polar hydrogen atoms were merged and rotatable bonds were defined for the ligand. The search grid of the JAK2 site was identified as center_x: 3.581, center_y: -11.802, and center_z: -1.188 with dimensions size_x: 15, size_y: 15, and size_z: 15. AutoDock Tools and PyMol were used to visually analyze the docking results.

**Molecular Dynamics (MD) Simulation**

The complex of JAK2 and AT-I constructed by the docking was energy-minimized during 5,000 minimization steps. After that, the system was gradually heated up to 300 K over 50 ps. This procedure was followed by 50 ps of NPT simulation at 300 K and 1 atm pressure to equilibrate the system. After equilibration, the systems were used to run 50ns long MD simulations. A time step of 2fs was used and coordinates of the system were saved every 20 ps. The resulting trajectory data were viewed and analyzed using the VMD software. Binding free energy was calculated by Molecular mechanics/generalized Born surface area (MM/GBSA).
**Tumor Xenograft Model**

The animal experiments were approved by the Animal Ethics Committee of China Medical University (No. CMU2019321). For xenograft studies, male BALB/c nude mice (six weeks old and 18-20 g each) were injected subcutaneously with HCT116 (5 × 10⁶ cells/100 μl) into the right flank. When the diameter of the tumor reached to approximately 5 mm, mice were randomly divided into control and treated group (6 mice each group). Control group of mice was intraperitoneally injection with vehicle (0.9% sodium chloride plus 0.1% DMSO) and treated group was administrated with AT-I (50 mg/kg body weight) once daily for 3 weeks. The body weight and tumor volume were measured every 3 days after treatment begin. Tumor volumes were calculated using the formula: tumor volume (mm³) = (long diameter × short diameter ²)/2. At the end of the study, tumors were removed and then weighed.

**Immunohistological Analysis**

For histological examination, dissected tumor tissues were fixed with 4% paraformaldehyde, embedded in paraffin and sectioned at 5 μm thicknesses. Levels of apoptosis in tumor tissue were determined using TdT-mediated dUTP-biotin nick end-labeling (TUNEL) assay with the in-situ Apoptosis Detection Kit (KeyGEN BioTECH, Nanjing, China) according to the manufacturer’s instructions. For immunohistochemical analysis of p-JAK2, p-STAT3 and HK2, the deparaffinized and hydrated sections were incubated with 0.3% H₂O₂ to block endogenous peroxidase activity and performed with sodium citrate buffer in a microwave for 20 min for antigen retrieval. Then the sections were incubated with the indicated antibodies overnight at 4°C followed by incubation with HRP-conjugated secondary antibody. 3,3′-Diaminobenzidine and hematoxylin were used to detect the immunocomplexes and nuclear counterstaining respectively. Finally, the tissue sections were captured with an Olympus digital camera attached to a light microscope.

**Statistical Analysis**

All results were obtained from experiments that were repeated at least three times. For comparison of the two groups, statistical significance was analyzed with Student’s t-test. Statistical significance for multiple groups was performed using one-way ANOVA with Tukey’s post hoc test. Values were expressed as the mean ± standard error (SD). Statistical significance was set at P < 0.05.

**RESULTS**

**AT-I Suppressed Proliferation of CRC Cells**

We initially investigated the potential anti-cancer properties of AT-I in CRC cell lines. We cultured two human CRC cell lines, HCT116 and SW480, in a medium containing 0-200 μM of AT-I for 24 and 48 h, and then evaluated cell viability using a CCK-8 assay. The results revealed that AT-I inhibited CRC cell viability in dose- and time-dependent manners, with half maximal inhibitory concentrations (IC50) of 126.8 μM and 97.19 μM for a 24 h treatment, and 98.49 μM and 70.44 μM for a 48 h treatment, respectively (Figure 1B). In addition, we also tested the cytotoxic effect of AT-I on normal cells NCM460. As shown in Figure 1B, AT-I exhibited as less cytotoxic against NCM460, with the IC50 values of more than 200 μM after 24 and 48 h treatment. To determine whether the decrease in viable cell density was due to an anti-proliferative effect of AT-I, we further measured the effect of AT-I on DNA replication using an EdU incorporation assay. The results showed that the numbers of EdU-positive cells were significantly reduced in both the SW480 and HCT116 lines after AT-I treatment for 24 h (Figure 1C). In addition, the anti-proliferative activity of AT-I was further evaluated using a colony formation assay. As shown in Figure 1D, there was a significant reduction in colony number after treatment with AT-I. Collectively, these findings indicate that AT-I inhibits CRC cell proliferation but has low cytotoxicity towards normal cells.

**AT-I Induced CRC Cell Apoptosis**

To determine whether AT-I-mediated inhibition of CRC cell proliferation is associated with apoptosis, we used DAPI staining to examine nuclear condensation (a characteristic of apoptosis). The results revealed prominent chromatin condensation and nuclear fragmentation in the AT-I-treated CRC cells (Figure 2A). To confirm the induction of apoptosis in response to AT-I treatment, we also assessed apoptosis using flow cytometric analysis after double labeling with Annexin V and PI. The results showed that AT-I treatment for 24 h increased the percentage of apoptotic CRC cells in a dose-dependent manner (Figure 2B). Given that activation of caspase-3 and cleavage of PARP are well-known molecular markers of apoptosis (Elmore, 2007), we next examined the levels of caspase-3 and PARP in CRC cells treated using AT-I. As shown in Figures 2C, D, AT-I triggered caspase-3 and PARP-1 cleavage as seen by the reduced expression of procaspase-3 and full length PARP and increased expression of cleavage of caspase-3 and PARP in a dose-dependent manner. An imbalance between the pro-apoptotic protein Bax and anti-apoptotic protein Bcl-2 would result in caspase-3 activation and subsequent apoptosis (Plati et al., 2011), and we found that AT-I dose-dependently downregulated Bcl-2 and upregulated Bax expression levels compared with the control group (Figures 2C, D). Collectively, these findings indicated that AT-I could efficiently induce apoptosis in CRC cells.

**AT-I Mediated Suppression of Glycolysis in CRC Cells via a Reduction in HK2 Expression**

Given that cancer cell proliferation and apoptosis are closely linked with glycolysis (Matsuura et al., 2016), we examined whether AT-I can be used to induce a metabolic shift in CRC cells. We found that after AT-I treatment, there was a significant dose-dependent decrease in glucose consumption by the CRC cells (Figure 3A). In addition, there was a significant decrease in
lactate secretion in the AT-I-treated CRC cells (Figure 3B). Therefore, we examined the expression of three key rate-limiting glycolytic enzymes (HK2, PFK, and PKM2) in CRC cells treated with AT-I. Western blot analysis revealed that HK2 expression decreased in response to the AT-I treatment, whereas the expression of PFK and PKM2 remained unaltered (Figures 3C, D). Collectively, these findings indicate that AT-I may suppress glycolysis in the CRC cells by reducing HK2 expression.
AT-I Inhibits JAK2/STAT3 Signaling Pathway in CRC Cells

Recent studies have shown that STAT3 is a transcription factor that regulates the transcription of HK2 (Jiang et al., 2012). Thus, we hypothesized that AT-I may regulate STAT3 activation in CRC cells. Phosphorylation of the Tyr705 residue of STAT3 appears to be an essential prerequisite for converting STAT3 to an active form (Levy and Lee, 2002). We found that AT-I suppresses the phosphorylation of STAT3 at Tyr705 in a dose-dependent manner without altering total STAT3 protein levels (Figures 4A, B). Considering the significant role of JAK2 in phosphorylation of the Tyr705 residue in STAT3 (Rawlings et al., 2004), we evaluated the activation of JAK2 in response to AT-I in CRC cells. As shown in Figures 4C, D, AT-I inhibited JAK2 phosphorylation in a dose-dependent manner. We therefore speculated as to whether JAK2 acts as a target of AT-I. To verify this hypothesis, we performed a computer docking analysis. The results showed that AT-I docks onto the binding site of human JAK2 (Figure 4E). AT-I was located at the hydrophobic site, surrounded by residues Leu-855, Phe-860, Val-863, Ala-880, Met-929, Leu-932, and Leu-983, forming strong hydrophobic binding. Importantly, we observed one key hydrogen bond interaction between AT-I and Leu-932 (bond length = 2.4 Å), which was the main interaction between AT-I and JAK2 (Figure 4F). All these interactions facilitated the anchoring of AT-I to the binding site of JAK2. Then we used MD simulations to evaluate the dynamic stability of the complexes of AT-I with JAK2. As shown in Figure 4G, the RMSD of docked AT-I-JAK2 complex and JAK2 apo all remain stable after a 25ns MD run. By contrast, the complex RMSD was more stable and lower than that of JAK2 apo. The total binding free energy between AT-I and JAK2 was -27.7 kcal/mol, indicating a well binding between them. Collectively, these results indicated that AT-I undergoes a strong interaction with JAK2 and this binding interaction may increase the structural stability of JAK2. To confirm the role of JAK2 in AT-I-induced STAT3 inactivation, we pretreated CRC cells with AG490 (10 μM), a JAK2 inhibitor, followed by treatment with AT-I. We accordingly found that the AT-I-induced decrease in STAT3 phosphorylation was enhanced by pretreating the CRC cells with AG490 (Figures 4H, I). We therefore conclude that AT-I inhibits JAK2 activity and thereby functions as an inhibitor of the JAK2/STAT3 signaling pathway.

Inactivated STAT3 Mediated the Inhibitory Activity of AT-I on the Glycolysis and HK2 Expression in CRC Cells

To further clarify the role of STAT3 in the regulatory effect of AT-I on glycolysis, we overexpressed STAT3 by transient transfection of a vector overexpressing STAT3 into CRC cells. After 24 h transfection, the expression of total STAT3 and STAT3 phosphorylation was increased remarkably in CRC cells (Figure 5A). Moreover, we found that when overexpression STAT3, AT-I-induced changes in the expression levels of HK2 were markedly
reversed (Figures 5B, C). Further, we also observed that STAT3 overexpression rescued the deficient glucose consumption and lactate production in the AT-I-treated CRC cells (Figures 5D, E). These results indicated that AT-I-induced glycolysis suppression via decreased HK2 expression in CRC cells is partly mediated by inactivation of STAT3.

**Anti-proliferation and Pro-apoptotic Activities of AT-I Are Associated With STAT3 Inactivation in CRC Cells**

In addition to mediating glycolysis, STAT3 activation is also involved in the proliferation and anti-apoptosis of cancer cells [24]. We therefore wondered whether STAT3 is involved in AT-
I-induced CRC cell apoptosis. After exogenously overexpressing STAT3 in CRC cells, the reduced cell viability caused by AT-I was partially reversed (Figure 6A). Moreover, the overexpression of STAT3 also reduced AT-I-induced apoptosis (Figure 6B). Consistent with these results, the effects of AT-I on apoptosis-related protein expression were significantly reversed after the overexpression of STAT3 in CRC cells (Figures 6C, D). These results indicated that STAT3 plays an important role in the anticancer effects mediated by AT-I in CRC cells.

AT-I Inhibits Tumor Growth of CRC In Vivo

In order to characterize the anti-cancer effects of AT-I in vivo, tumors of xenograft formed by the HCT116 cell were used. As shown in Figure 7A, during the three week treatment, AT-I significantly decreased tumor volume, when compared with the control group. Moreover, tumor weight of mice in AT-I treated group was markedly lower than that of the mice in the control group at the end of the treatment (Figure 7B). However, we observed that no significant difference in the body weight of mice between the control and AT-I-treated groups (Figure 7C), suggesting that AT-I has no obvious toxicity. Additionally, we detected apoptosis in xenografts mice using a TUNEL assay. We observed that AT-I increased the number of TUNEL-positive cells in the AT-I-treated group confirming that AT-I could induce apoptosis in vivo (Figure 7D). Consistent with the in vitro results, immunohistological analysis revealed that AT-I downregulated the expression of HK2, p-JAK2 and p-STAT3 in tumor tissues of the xenograft mice (Figure 7D). Collectively, these in vivo data suggested that AT-I could induce CRC suppression through inhibiting JAK2/STAT3-dependent regulation of HK2 in tumors.

DISCUSSION

The current focus regarding the development of CRC treatment strategies is on discovering novel natural drugs with greater efficacy against cancer cells and lower toxicity toward normal cells (Rejhova et al., 2018). Rhizoma Atractylodis macrocephalae is a typical Chinese herbal medicine that has been reported to have diverse pharmacological effects (Zhu et al., 2018). A natural compound isolated from this plant, AT-I, has attracted increasing attention on account of its anti-cancer properties. In this study, we assessed the anti-cancer properties of AT-I against two CRC cell lines (HCT116 and SW480). We initially demonstrated that AT-I significantly inhibited the proliferation of tumor cells by using CCK-8, EdU and colony formation assay. However, AT-I showed comparatively less cytotoxicity towards the normal colon epithelial cell, indicating that AT-I selectively
targeted CRC cells. This is encouraging for further research on AT-I as potential drugs against CRC.

Given that many types of cancer cell show disruption of the programmed death pathway, apoptosis represents a key therapeutic target in the treatment of cancer (Wong, 2011). Among the family of caspases, Caspase-3 has been regarded as a major executioner in apoptosis, and its activation promotes the down-streaming signal of PARP, subsequently contributing to cell death (Cohen, 1997).
Usually the cleavage of PARP is used as an indicator of apoptosis (Wang et al., 1997). Here, we found that AT-I significantly induced cleavage of caspase-3. Subsequently, cleaved PARP was elevated. Mitochondria are also centrally involved in apoptosis (Wang, 2001). In response to diverse stimuli, Bcl-2 family plays a crucial role in initiating the intrinsic apoptotic pathway through modulation of anti-apoptotic (Bcl-2 and Bcl-xl) and pro-apoptotic (Bax and Bak) members (Wong and Puthalakath, 2008). Overexpression of bax is capable of promoting cytosolic accumulation of cytochrome c released from mitochondria and accordingly impels cell death. On the other hand, inhibition of cytochrome c release is governed by Bcl-2 (Ola et al., 2011). It has been proved that application of AT-I can altered the expressions of Bcl-2 family to promote cancer cells apoptosis (Liu et al., 2013; Long et al., 2017). Several natural compounds have been found to regulate glycolysis by targeting these glycolytic enzymes. For example, curcumin, a bioactive compound from the herb Curcuma aromatica Salisb, suppresses HK2 expression and leads to reduced glycolysis in CRC cells (Wang et al., 2015). Resveratrol, a polyphenolic compound, decreases cell viability and glucose metabolism by inhibiting PFK in breast cancer (Gomez et al., 2013). Shikonin, which is derived from Lithospermum erythrorhizon, has been shown to inhibit cancer cell glycolysis by specifically targeting PKM2 (Chen et al., 2011). Given the importance of these enzymes, we assessed their expression in CRC cells upon AT-I treatment and found that downregulation of HK2 expression in response to treatment with AT-I had no discernable effect on PFK or PKM2. These results indicated that AT-I can suppress CRC cell glycolysis by reducing the levels of HK2 expression.

As an important metabolic indicator, the Warburg effect facilitates cancer cell malignancy by increasing biosynthesis within cells, thereby promoting enhanced growth and proliferation (Tennant et al., 2010). In the present study, we assessed how AT-I alters glycolytic parameters in CRC cells and found that this agent inhibits both glucose uptake and lactate production. Overexpression of rate-limiting glycolytic enzymes, including HK, PFK, and PKM2, is a common characteristic of the Warburg effect (Mikawa et al., 2015). The HK2 isoenzyme is the form of HK that is most common in tumors, and is associated with tumor initiation and maintenance (Patra et al., 2013). PFK catalyzes the conversion of fructose-6-phosphate to fructose-1,6-bisphosphate and it is considered vital to cancer cell metabolic reprogramming (Al Hasawi et al., 2014). PKM2 regulates the first step of glycolysis, and is thus amongst the most important regulators of tumor cell metabolism (Christofk et al., 2008).

Several studies have provided evidence that indicates an association between aberrant phosphorylation of the transcription factor STAT3 and a wide variety of cancers (Yu et al., 2014). STAT3 regulates the expression of essential genes that mediate cancer.

FIGURE 7 | AT-I inhibits the growth of CRC cells in a nude mice xenograft Assay. Mice were administrated with vehicle or AT-I at 50 mg/kg/day for 3 weeks. Tumor volumes (A), tumor weight (B) and body weight (C) of mice were measured. (D) Histological analysis of TUNEL, HK2, p-JAK2 and p-STAT3 levels in tumor tissue sections. Left: representative images of immunohistochemical analysis of tumor sections. Scale bar = 100 μm. Right: quantification of the percentage of positive cells in tumors. Data are represented as mean ± SD. **p < 0.001 versus the Ctrl group.
Moreover, STAT3 overexpression significantly increases the levels of p-STAT3 in CRC cells and, as expected, the anti-JAK2 activity of AT-I. Both AT-I and AG490 can reduce JAK2 phosphorylation in a dose-dependent manner. Moreover, several studies have reported that JAK2 can markedly reduce JAK2 phosphorylation in a dose-dependent manner. In vivo, AT-I significantly inhibited tumour growth and reduced the expression of HK2, phosphorylated JAK2 and STAT3. These findings indicate that AT-I may inhibit the JAK2/STAT3 signaling pathway by directly interacting with JAK2 and exerting its activity against CRC cells by inducing apoptosis and metabolic shifts.

In summary, the results of this study showed that AT-I suppresses CRC cell growth in vitro and in vivo. The anti-cancer properties of AT-I can be attributed to apoptosis and suppression of glycolysis, which, in turn, are mediated via AT-I-induced downregulation of HK2. Finally, the anti-cancer efficacy of AT-I in CRC is essentially mediated by inactivation of the JAK2/STAT3 signaling pathway. The findings of this study provide insights that can provide a basis for the potential development of a JAK2/STAT3 signaling inhibitor, which could be administered in combination with other drugs for the therapeutic treatment of CRC.

DATA AVAILABILITY STATEMENT

The raw data supporting the conclusions of this article will be made available by the authors, without undue reservation, to any qualified researcher.

ETHICS STATEMENT

All protocols involving animal experiments were in accordance with the Care and Use of Laboratory Animals and approved by Animal Ethics Committee of China Medical University.

AUTHOR CONTRIBUTIONS

ZM and SM, the corresponding authors, conceived and designed the research. YL, YW, ZL, and XG performed the experiments, analyzed data, and prepared figures. YL, YW, and ZM drafted this manuscript. All authors contributed to manuscript and reviewed and approved the manuscript.

FUNDING

This work was funded by Clinical Capability Construction Project for Liaoning Provincial Hospitals (LNCCC-D44-2015), and Natural Science Foundation of Liaoning Province (201602447).

REFERENCES

Al Hasawi, N., Alkandari, M. F., and Luqmani, Y. A. (2014). Phosphofructokinase: a mediator of glycolytic flux in cancer progression. Crit. Rev. Oncol. Hematol. 92 (3), 312–321. doi: 10.1016/j.critrevonc.2014.05.007

Arnold, M., Sierra, M. S., Laversanne, M., Soejmomataram, I, Jemal, A., and Bray, F. (2017). Global patterns and trends in colorectal cancer incidence and mortality. Gut 66 (4), 683–691. doi: 10.1136/gutjnl-2015-310912

Bensinger, S. J., and Christofk, H. R. (2012). New aspects of the Warburg effect in cancer cell biology. Semin. Cell Dev. Biol. 23 (4), 352–361. doi: 10.1016/j.semcdb.2012.02.003

Bowman, T., Garcia, R., Turkson, J., and Jove, R. (2000). STATs in oncogenesis. Oncogene 19 (21), 2474–2488. doi: 10.1038/sj.onc.1203527

Bray, F., Ferlay, J., Soerjomataram, I. Siegel, R. L., Torre, L. A., and Jemal, A. (2018). Global cancer statistics 2018: GLOBOCAN estimates of incidence and
Levy, D. E., and Lee, C.-k. (2002). What does Stat3 do?

He, K., Zheng, X., Li, M., Zhang, L., and Yu, J. (2016). mTOR inhibitors induce apoptosis in colon cancer cells via CHOP-dependent DR5 induction on 4E-BP1 dephosphorylation.

Jiang, S., Zhang, L. F., Zhang, H. W., Hu, S., Lu, M. H., Liang, S., et al. (2012). A novel miR-153/miR-143 cascade controls glycolysis by regulating hexokinase 2 (HK2).

Christofk, H. R., Vander Heiden, M. G., Harris, M. H., Ramanathan, A., Gerszten, R. E., Wei, R., et al. (2008). The M2 splice isoform of pyruvate kinase is essential for cancer metabolism and tumour growth.

Cohen, G. M. (1997). Caspases: the executioners of apoptosis.

Liu, B., and Yu, S. (2018). Amentoflavone suppresses hepatocellular carcinoma by repressing hexokinase 2 expression through inhibiting AK2/STAT3 signaling.

Li et al. Anti-CRC Effect of Atractylenolide I

Liu, H., Zhu, Y., Zhang, T., Zhao, Z., Zhao, Y., Cheng, P., et al. (2013). Anti-tumor effects of atracylenolide I isolated from Atractylodes macrocephala in human lung cancer cell line Molec. Med. 10 (11), 13357–13368. doi:10.3390/molecules18113357

Long, F., Wang, T., Jia, P., Wang, H., Qing, Y., Xiong, T., et al. (2017). Anti-Tumor Effects of Atracylenolide-I on Human Ovarian Cancer Cells. Med. Sci. Monit. 23, 571–579. doi: 10.12659/msm.902886

Matsuura, K., Canfield, K., Feng, W., and Kurokawa, M. (2016). Metabolic Regulation of Apoptosis in Cancer. Int. Rev. Cell Mol. Biol. 327, 43–87. doi:10.1016/bs.cimb.2016.06.006

Mikawa, T., ME, L., Takaori-Kondo, A., Inagaki, N., Yokode, M., and Kondoh, H. (2015). Disregulated glycolysis as an oncogenic event. Cell Mol. Life Sci. 72 (10), 1881–1892. doi:10.1007/s00018-015-1840-3

More, S., and Choi, D. K. (2017). Neuroproteptive Role of Atractylolide-I in an In Vitro and In Vivo Model of Parkinson’s Disease. Nutrients 9, 4511. doi:10.3390/nu90705451

Ola, M. S., Nawaz, M., and Ahsan, H. (2011). Role of Bel-2 family proteins and caspases in the regulation of apoptosis. Mol. Cell Biochem. 351 (1-2), 41–58. doi:10.1007/s11010-010-0709-x

Patra, K. C., Wang, Q., Bhaskar, P. T., Miller, L., Wang, Z., Wheaton, W., et al. (2013). Hexokinase 2 is required for tumor initiation and maintenance and its systemic deletion is therapeutic in mouse models of cancer. Cancer Cell 24 (2), 213–228. doi:10.1016/j.ccc.2013.06.014

Pelcino, H., Martin, D. S., Xu, R. H., and Huang, P. (2006). Glycolysis inhibition for cancer treatment. Oncotarget. 157.6363–6366. doi:10.1038/joicb00144a

Plati, J., Bucur, O., and Khorasani-Far, R. (2011). Apoptotic cell signaling in cancer progression and therapy. Integr. Biol. (Camb) 3 (4), 279–296. doi:10.1039/c1ib00144a

Rawlings, J. S., Rosler, K. M., and Harrison, D. A. (2004). The JAK/STAT signaling pathway. J. Cell Sci. 117 (Pt 8), 1281–1283. doi:10.1242/jcs.009663

Rejihova, A., Opattova, A., Cumova, A., Sliva, D., and Vodicka, P. (2018). Natural compounds and combination therapy in colorectal cancer treatment. Eur. J. Med. Chem. 144, 582–594. doi:10.1016/j.ejmech.2017.12.039

Scatena, R., Bottino, P., Pontoglio, A., Mastroットaro, L., and Giardino, B. (2008). Glycolytic enzyme inhibitors in cancer treatment. Expert Opin. Invest. Drugs 17 (10), 1533–1545. doi:10.1517/13543784.17.10.1533

Tennant, D. A., Duran, R. V., and Gottlieb, E. (2010). Targeting metabolic transformation for cancer therapy. Nat. Rev. Cancer 10 (4), 267–277. doi:10.1038/nrc2817

Wang, Z. Q., Stingl, L., Morrison, C., Jantsch, M., Los, M., and Vehrs, O. (1999). Parp is important for genomic stability but dispensable in apoptosis. Genes Dev. 11 (18), 2347–2358. doi:10.1101/gad.11.18.2347

Wang, C., Wang, S., Chen, Q., and He, L. (2008). A capillary gas chromatography-selected ion monitoring mass spectrometry method for the analysis of atracylenolide-I in rat plasma and tissues, and application in a pharmacokinetic study. J. Chromatogr. B Anal. Technol. BioMed. Life Sci. 863 (2), 213–222. doi:10.1016/j.jchromb.2008.01.004

Wang, C., Duan, H., and He, L. (2009). Inhibitory effect of atracylenolide-I on angiogenesis in chronic inflammation in vivo and in vitro. Eur. J. Pharmacol. 612 (1-3), 143–152. doi:10.1016/j.ejphar.2009.04.001

Wang, K., Fan, H., Chen, Q., Ma, G., Zhu, M., Zhang, X., et al. (2015). Curcumin inhibits aerobic glycolysis and induces mitochondrial-mediated apoptosis through hexokinase II in human colorectal cancer cells in vitro. Anticancer Drugs 26 (1), 15–24. doi:10.1016/j.acdbio.2013.01.012

Wang, X. (2001). The expanding role of mitochondria in apoptosis. J. Exp. Biol. 204, 4273–4283. doi:10.1242/jeb.1283

Wong, R. S. (2011). Apoptosis in cancer: from pathogenesis to treatment.

Enhancement of Atractylenolide-I and Erlotinib in the Inhibition of Human Lung Cancer Cell Growth by PDK1- and LncRNA HOTAIR-Mediated EZH2 Gene Expression Contributes to the Anti-Cancer Effect of Atractylenolide-I on Human Ovarian Cancer Cells. Nutrients 13368. doi:10.3390/molecules18113357

Anticancer Drugs 26 (1), 15–24. doi:10.1016/j.acdbio.2013.01.012

Anti-CRC Effect of Atractylenolide I

Ann. Pharmacother. 107, 243–253. doi:10.1016/j.biopharma.2018.07.177

Liu, Y., Jia, Z., Dong, L., Wang, R., and Qiu, G. (2008). A randomized pilot study of atracylenolide-I on gastric cancer cachexia patients. Evid Based Complement Altern. Med. 5 (3), 337–344. doi:10.1093/ecam/nem031

Frontiers in Pharmacology | www.frontiersin.org March 2020 | Volume 11 | Article 2737

10.3390/nu90705451
Yang, J., Yuan, D., Xing, T., Su, H., Zhang, S., Wen, J., et al. (2016). Ginsenoside Rh2 inhibiting HCT116 colon cancer cell proliferation through blocking PDZ-binding kinase/T-LAK cell-originated protein kinase. *J. Ginseng Res.* 40 (4), 400–408. doi: 10.1016/j.jgr.2016.03.007

Yu, H., Lee, H., Herrmann, A., Buettner, R., and Jove, R. (2014). Revisiting STAT3 signalling in cancer: new and unexpected biological functions. *Nat. Rev. Cancer* 14 (11), 736–746. doi: 10.1038/nrc3818

Yu, R., Yu, B. X., Chen, J. F., Lv, X. Y., Yan, Z. J., Cheng, Y., et al. (2016). Anti-tumor effects of Atractylenolide I on bladder cancer cells. *J. Exp. Clin. Cancer Res.* 35, 40. doi: 10.1186/s13046-016-0312-4

Zhang, P., Lai, Z. L., Chen, H. F., Zhang, M., Wang, A., Jia, T., et al. (2017). Curcumin synergizes with 5-fluorouracil by impairing AMPK/ULK1-dependent autophagy, AKT activity and enhancing apoptosis in colon cancer cells with tumor growth inhibition in xenograft mice. *J. Exp. Clin. Cancer Res.* 36 (1), 190. doi: 10.1186/s13046-017-0661-7

Zhu, B., Zhang, Q. L., Hua, J. W., Cheng, W. L., and Qin, L. P. (2018). The traditional uses, phytochemistry, and pharmacology of Atractylodes macrocephala Koidz: A review. *J. Ethnopharmacol.* 226, 143–167. doi: 10.1016/j.jep.2018.08.023

**Conflict of Interest:** The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

**Copyright © 2020 Li, Wang, Liu, Guo, Miao and Ma. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.**